Cervavac and gardasil comparison
Both Cervavac and Gardasil are HPV vaccines, but differ in origin, valency, and some formulation details. Cervavac is India's first indigenously developed quadrivalent HPV vaccine (by Serum Institute of India), while Gardasil comes in two versions - quadrivalent (Gardasil 4) and 9-valent (Gardasil 9) by Merck.
Searching sources...
Reading File
Searching the Web
Cervavac vs Gardasil HPV vaccine comparison 2024 2025
Searching PubMed
Cervavac HPV vaccine immunogenicity efficacy
Reading Article
PMID: 37949086
Reading Web Page
https://www.mdpi.com/2076-393X/14/2/140
Finding Sources
Here is a detailed comparison of Cervavac and Gardasil:
Cervavac vs. Gardasil - HPV Vaccine Comparison
Overview
| Feature | Cervavac | Gardasil (4-valent) | Gardasil 9 |
|---|---|---|---|
| Manufacturer | Serum Institute of India (SIIPL) | Merck Sharp & Dohme | Merck Sharp & Dohme |
| Origin country | India | USA/Netherlands | USA |
| Valency | Quadrivalent | Quadrivalent | Nonavalent |
| Approval year | 2022 (DCGI, India) | 2006 (FDA) | 2014 (FDA) |
| WHO Prequalification | Not prequalified (as of 2025) | WHO prequalified (2009) | WHO prequalified (2018) |
| Technology platform | VLP (yeast-derived) | VLP (yeast-derived) | VLP (yeast-derived) |
HPV Types Covered
| Vaccine | Types Covered | Protection Against |
|---|---|---|
| Cervavac | 6, 11, 16, 18 | ~70% cervical cancers + genital warts |
| Gardasil (4v) | 6, 11, 16, 18 | ~70% cervical cancers + genital warts |
| Gardasil 9 | 6, 11, 16, 18, 31, 33, 45, 52, 58 | ~90% cervical cancers + genital warts |
Both Cervavac and Gardasil 4v cover exactly the same HPV types. Gardasil 9 has broader coverage.
Immunogenicity (Key Clinical Trial Data)
The pivotal Phase II/III trial published in The Lancet Oncology (2023) directly compared Cervavac vs. Gardasil in India across 12 tertiary care hospitals (n = 2,307 participants):
- Non-inferiority established: Cervavac generated GMT (geometric mean titres) for all 4 HPV types (6, 11, 16, 18) that were non-inferior to Gardasil in the 9-14 year age group (using 2-dose schedule at months 0 and 6).
- Age groups studied: 9-14 years (2-dose) and 15-26 years (3-dose).
- Males included: Boys aged 9-14 years received Cervavac in open-label fashion - a notable inclusion for an Indian trial.
- The non-inferiority margin used was a lower bound of the 98.75% CI of the GMT ratio ≥ 0.67.
A 2025 state-of-the-art review in Vaccines (MDPI) confirmed: "Cervavac showed non-inferior immunogenicity compared with established vaccines," but noted that direct long-term clinical efficacy data on disease prevention are not yet available - protection is inferred from immunological equivalence.
Dosing Schedule
| Age Group | Cervavac | Gardasil (4v) |
|---|---|---|
| 9-14 years | 2 doses (0 and 6 months) | 2 doses (0 and 6-12 months) |
| 15 years and older | 3 doses (0, 2, 6 months) | 3 doses (0, 2, 6 months) |
| Males (9-14 y) | 2 doses | 2 doses |
Both vaccines require completion of the series with the same product - switching mid-course is not recommended for Cervavac, and there are no interchangeability data for Gardasil (4v) with Cervavac.
Safety Profile
From the Lancet Oncology Phase 2/3 trial:
- Both vaccines had comparable safety profiles.
- Most adverse events were local reactions (injection site pain, swelling, redness) and mild systemic events (fever, headache).
- No significant difference in serious adverse events between the two vaccines.
Cost and Access
| Factor | Cervavac | Gardasil |
|---|---|---|
| Price (India) | ~INR 2,000 per dose (significantly lower) | ~INR 3,000-4,000 per dose |
| Target market | LMIC countries, especially India | Global; higher-income markets |
| Purpose | To improve vaccine access and affordability in India and LMICs | Established global brand |
Cervavac was developed specifically to address affordability barriers in low- and middle-income countries (LMICs). India's national immunization program began incorporating Cervavac to expand access.
Key Differences Summarized
- Same HPV coverage: Both Cervavac and Gardasil 4v protect against the same 4 HPV types (6, 11, 16, 18). Gardasil 9 offers broader protection.
- Proven non-inferior immunogenicity: Cervavac is not inferior to Gardasil in head-to-head trials.
- No long-term efficacy data yet: Cervavac lacks the decades of real-world effectiveness data Gardasil has accumulated - protection is extrapolated from immunogenicity equivalence.
- WHO prequalification: Gardasil is WHO-prequalified; Cervavac is not (as of mid-2025), limiting its use in UN-procured vaccination campaigns.
- Cost advantage: Cervavac is significantly cheaper, making it the preferred option in India's public health immunization efforts.
- Interchangeability: Not recommended between the two - complete the series with whichever vaccine you start.
Bottom Line
Cervavac is a clinically validated, affordable Indian alternative to Gardasil 4v with identical HPV type coverage and proven immunological equivalence. For maximum HPV coverage (including types 31, 33, 45, 52, 58), Gardasil 9 remains the gold standard globally where affordability is not a barrier. The Lancet Oncology RCT (PMID: 37949086) is the key evidence base establishing Cervavac's non-inferiority.
This is a shared conversation. Sign in to Orris to start your own chat.